Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Oct 08, 2010 |
approval memo.29 |
Oct 01, 2010 |
signed chap.536 |
Sep 20, 2010 |
delivered to governor |
Jun 23, 2010 |
returned to senate passed assembly ordered to third reading rules cal.291 substituted for a8278b |
Jun 23, 2010 |
substituted by s5000b rules report cal.291 reported |
Jun 16, 2010 |
reported referred to rules |
Jun 09, 2010 |
reported referred to codes |
May 10, 2010 |
print number 8278b |
May 10, 2010 |
amend and recommit to insurance |
Jan 13, 2010 |
print number 8278a |
Jan 13, 2010 |
amend and recommit to insurance |
Jan 06, 2010 |
referred to insurance |
May 12, 2009 |
referred to insurance |
Assembly Bill A8278
Signed By Governor2009-2010 Legislative Session
Sponsored By
KELLNER
Archive: Last Bill Status Via S5000 - Signed by Governor
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
Votes
Bill Amendments
co-Sponsors
Richard Gottfried
Robert Reilly
David Koon
Rhoda Jacobs
multi-Sponsors
Daniel Burling
Deborah Glick
David McDonough
John McEneny
2009-A8278 - Details
- Law Section:
- Public Health Law
- Laws Affected:
- Amd §4406-c, Pub Health L; amd §§3216, 3221 & 4303, Ins L; amd §296, Exec L
2009-A8278 - Summary
Provides that no health care plan or health insurance policy which provides coverage for prescription drugs and for which cost-sharing, deductibles or co-insurance obligations are determined by category of prescription drugs including, but not limited to, generic drugs, preferred brand drugs and non-preferred brand drugs, shall impose cost-sharing, deductibles or co-insurance obligations for any prescription drug that exceeds the dollar amount of cost-sharing, deductibles or co-insurance obligations for any other prescription drug provided under such coverage in the category of non-preferred brand drugs or their equivalents.
2009-A8278 - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 8278 2009-2010 Regular Sessions I N A S S E M B L Y May 12, 2009 ___________ Introduced by M. of A. KELLNER, GOTTFRIED -- read once and referred to the Committee on Insurance AN ACT to amend the public health law and the insurance law, in relation to cost-sharing, deductible or co-insurance for tier IV prescription drugs; and to amend the executive law, in relation to unlawful discri- minatory practice in relation to tier IV prescription drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative findings. The cost-sharing, deductibles and co-insurance obligations for certain drugs have become cost prohibitive for persons trying to overcome serious diseases such as cancer, multiple sclerosis, rheumatoid arthritis, hepatitis C, and hemophilia. These drugs are typically new, produced in lesser quantities than other drugs, and not available as less expensive brand name or generic prescription drugs. Some health insurance plans and policies have established unique categories or specialty tiers for these drugs, sometimes referred to as Tier IV or Tier V. Patients under these plans are required to pay a percentage of the cost of these high-priced drugs, rather than the traditional co-payment amounts for generic, preferred brand, and non- preferred brand prescription drugs, often covered by Tier I, Tier II, and Tier III plans and policies, respectively. As a result, patients covered under Tier IV or Tier V plans or policies must pay thousands of dollars in out-of-pocket costs for drugs critical for their treatment. It is in the public interest to help patients to afford necessary prescription drugs by prohibiting cost-sharing, deductibles and co-insu- rance obligations by patients that exceed payments for non-preferred brand prescription drugs or the equivalent thereof. It is not the intent of this legislation to preclude plans or policies from categorizing drugs used in the treatment of these common diseases as brand name prescription drugs or generic prescription drug equivalents. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD11409-01-9
co-Sponsors
Richard Gottfried
Robert Reilly
David Koon
Rhoda Jacobs
multi-Sponsors
Richard Brodsky
Daniel Burling
Deborah Glick
George Latimer
2009-A8278A - Details
- Law Section:
- Public Health Law
- Laws Affected:
- Amd §4406-c, Pub Health L; amd §§3216, 3221 & 4303, Ins L; amd §296, Exec L
2009-A8278A - Summary
Provides that no health care plan or health insurance policy which provides coverage for prescription drugs and for which cost-sharing, deductibles or co-insurance obligations are determined by category of prescription drugs including, but not limited to, generic drugs, preferred brand drugs and non-preferred brand drugs, shall impose cost-sharing, deductibles or co-insurance obligations for any prescription drug that exceeds the dollar amount of cost-sharing, deductibles or co-insurance obligations for any other prescription drug provided under such coverage in the category of non-preferred brand drugs or their equivalents.
2009-A8278A - Sponsor Memo
BILL NUMBER:A8278A TITLE OF BILL: An act to amend the public health law and the insurance law, in relation to cost-sharing, deductible or co-insurance for tier IV prescription drugs; and to amend the executive law, in relation to unlawful discriminatory practice in relation to tier IV prescription drugs PURPOSE: This bill would prohibit commercial health insurance plans from creating specialty tiers within their prescription drug formular- ies. SUMMARY OF PROVISIONS: Section I: Legislative findings Section 2: Amends Section 4406-c of the public health law to prohibit the creation of specialty tiers. Sections 3, 4, 5 and 6: Conforming amendments to insurance law to prohibit the creation of specialty tiers. Section 7: Amends executive law to provide that creation of specialty tiers is unlawful discriminatory practice. Section 8: Severability clause. Section 9: Provides for effective date of 30 days after enactment.
2009-A8278A - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 8278--A 2009-2010 Regular Sessions I N A S S E M B L Y May 12, 2009 ___________ Introduced by M. of A. KELLNER, GOTTFRIED, REILLY, KOON, JACOBS, CYMBROWITZ, COOK, LANCMAN, ROSENTHAL, BOYLAND, ESPAILLAT, GUNTHER, BENEDETTO, JAFFEE, MENG, CAHILL, V. LOPEZ, GALEF, HOOPER -- Multi- Sponsored by -- M. of A. BURLING, GLICK, McDONOUGH, McENENY, PERRY, SCHIMEL, SWEENEY, THIELE, TITONE, WEISENBERG -- read once and referred to the Committee on Insurance -- recommitted to the Committee on Insurance in accordance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee AN ACT to amend the public health law and the insurance law, in relation to cost-sharing, deductible or co-insurance for tier IV prescription drugs; and to amend the executive law, in relation to unlawful discri- minatory practice in relation to tier IV prescription drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative findings. The cost-sharing, deductibles and co-insurance obligations for certain drugs have become cost prohibitive for persons trying to overcome serious diseases such as cancer, multiple sclerosis, rheumatoid arthritis, hepatitis C, and hemophilia. These drugs are typically new, produced in lesser quantities than other drugs, and not available as less expensive brand name or generic prescription drugs. Some health insurance plans and policies have established unique categories or specialty tiers for these drugs, sometimes referred to as Tier IV or Tier V. Patients under these plans are required to pay a percentage of the cost of these high-priced drugs, rather than the traditional co-payment amounts for generic, preferred brand, and non- preferred brand prescription drugs, often covered by Tier I, Tier II, and Tier III plans and policies, respectively. As a result, patients covered under Tier IV or Tier V plans or policies must pay thousands of dollars in out-of-pocket costs for drugs critical for their treatment. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD11409-03-0
co-Sponsors
Richard Gottfried
Robert Reilly
David Koon
Rhoda Jacobs
multi-Sponsors
Richard Brodsky
Daniel Burling
Deborah Glick
George Latimer
2009-A8278B (ACTIVE) - Details
- Law Section:
- Public Health Law
- Laws Affected:
- Amd §4406-c, Pub Health L; amd §§3216, 3221 & 4303, Ins L; amd §296, Exec L
2009-A8278B (ACTIVE) - Summary
Provides that no health care plan or health insurance policy which provides coverage for prescription drugs and for which cost-sharing, deductibles or co-insurance obligations are determined by category of prescription drugs including, but not limited to, generic drugs, preferred brand drugs and non-preferred brand drugs, shall impose cost-sharing, deductibles or co-insurance obligations for any prescription drug that exceeds the dollar amount of cost-sharing, deductibles or co-insurance obligations for any other prescription drug provided under such coverage in the category of non-preferred brand drugs or their equivalents.
2009-A8278B (ACTIVE) - Sponsor Memo
BILL NUMBER:A8278B TITLE OF BILL: An act to amend the public health law and the insurance law, in relation to cost-sharing, deductible or co-insurance for tier IV prescription drugs; and to amend the executive law, in relation to unlawful discriminatory practice in relation to tier IV prescription drugs PURPOSE OR GENERAL IDEA OF BILL: This bill will prohibit commercial health insurance plans from creating specialty tiers within their prescription drug formularies. SUMMARY OF SPECIFIC PROVISIONS: Section 1: Legislative findings. Section 2: Amends Section 4406-c of the public health law to prohibit the creation of specialty tiers. Sections 3, 4 and 5: Conforming amendments to insurance law to prohibit the creation of specialty tiers. Section 6: Amends executive law to provide that creation of specialty tiers is unlawful discriminatory practice.
2009-A8278B (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 8278--B 2009-2010 Regular Sessions I N A S S E M B L Y May 12, 2009 ___________ Introduced by M. of A. KELLNER, GOTTFRIED, REILLY, KOON, JACOBS, CYMBROWITZ, COOK, LANCMAN, ROSENTHAL, BOYLAND, ESPAILLAT, GUNTHER, BENEDETTO, JAFFEE, MENG, CAHILL, V. LOPEZ, GALEF, HOOPER, POWELL, SPANO, CASTRO, MAISEL, PEOPLES-STOKES, P. RIVERA, HEVESI -- Multi- Sponsored by -- M. of A. BRODSKY, BURLING, GLICK, LATIMER, LIFTON, LUPARDO, McDONOUGH, McENENY, J. MILLER, PAULIN, PERRY, PHEFFER, PRET- LOW, SCHIMEL, SWEENEY, THIELE, TITONE, TOWNS, WEISENBERG -- read once and referred to the Committee on Insurance -- recommitted to the Committee on Insurance in accordance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- again reported from said committee with amendments, ordered reprinted as amended and recommitted to said committee AN ACT to amend the public health law and the insurance law, in relation to cost-sharing, deductible or co-insurance for tier IV prescription drugs; and to amend the executive law, in relation to unlawful discri- minatory practice in relation to tier IV prescription drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative findings. The cost-sharing, deductibles and co-insurance obligations for certain drugs are becoming cost prohibitive for persons trying to overcome serious and often life-threatening diseases and conditions such as cancer, multiple sclerosis, rheumatoid arthritis, hepatitis C, hemophilia and psoriasis. These drugs are typi- cally new, produced in lesser quantities than other drugs, and not available as less expensive brand name or generic prescription drugs. Some health insurance plans and policies in other states as well as some self-insured plans in New York have established unique categories or specialty tiers for these drugs, sometimes referred to as Tier IV or Tier V. Patients under these plans are required to pay a percentage of the cost of these high-priced drugs, rather than the traditional co-pay- EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD11409-04-0
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.